Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Patgogenesis and management issues for non-alcocholic fatty liver disease (CROSBI ID 141760)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Duvnjak, Marko ; Lerotić, Ivan ; Baršić, Neven ; Tomašić, Vedran ; Virović-Jukić, Lucija, Velagić, Vedran Patgogenesis and management issues for non-alcocholic fatty liver disease // World journal of gastroenterology, 13 (2007), 34; 4539-4550

Podaci o odgovornosti

Duvnjak, Marko ; Lerotić, Ivan ; Baršić, Neven ; Tomašić, Vedran ; Virović-Jukić, Lucija, Velagić, Vedran

engleski

Patgogenesis and management issues for non-alcocholic fatty liver disease

Non-alcoholic fatty liver disease, Metabolic syndrome, Obesity, Insulin resistance, Liver fibrosis, NAFLD treatment Sažetak: Nonalcoholic fatty liver disease (NAFLD) has, although it is a very common disorder, only relatively recently gained broader interest among physicians and scientists. Fatty liver has been documented in up to 10 to 15 percent of normal individuals and 70 to 80 percent of obese individuals. Although the pathophysiology of NAFLD is still subject to intensive research, several players and mechanisms have been suggested based on the substantial evidence. Excessive hepatocyte triglyceride accumulation resulting from insulin resistance is the first step in the proposed 'two hit' model of the pathogenesis of NAFLD. Oxidative stress resulting from mitochondrial fatty acids oxidation, NF-kappaB-dependent inflammatory cytokine expression and adipocytokines are all considered to be the potential factors causing second hits which lead to hepatocyte injury, inflammation and fibrosis. Although it was initially believed that NAFLD is a completely benign disorder, histologic follow-up studies have showed that fibrosis progression occurs in about a third of patients. A small number of patients with NAFLD eventually ends up with end-stage liver disease and even hepatocellular carcinoma. Although liver biopsy is currently the only way to confirm the NAFLD diagnosis and distinguish between fatty liver alone and NASH, no guidelines or firm recommendations can still be made as for when and in whom it is necessary. Increased physical activity, gradual weight reduction and in selected cases bariatric surgery remain the mainstay of NAFLD therapy. Studies with pharmacologic agents are showing promising results, but available data are still insufficient to make specific recommendations ; their use therefore remains highly individual.

Non-alcoholic fatty liver disease; Metabolic syndrome; Obesity; Insulin resistance; Liver fibrosis; NAFLD treatment

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

13 (34)

2007.

4539-4550

objavljeno

1007-9327

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost